Antiepileptic drug therapy in children can be challenging because seizure semiology and drug disposition change dramatically over time. Close monitoring of drug clearance is required in early life because of the rapid ontogenesis of drug-eliminating organs. Large variations in serum peak and trough antiepileptic drug concentrations increase the risk for both adverse drug effects and unsatisfactory seizure control. Antiepileptic drug adverse effects also differ, probably relative to different receptor sensitivities in children. Failure to appreciate the developmental differences between children and adults can result in medication noncompliance, breakthrough seizures, and unacceptable adverse effects. (J Child Neurol 1994;9(Suppl):S20-S25).
Get full access to this article
View all access options for this article.
References
1.
Hauser WA, Kurland LT: The epidemiology of epilepsy in Rochester, Minnesota. Epilepsia1975;16:1-66.
2.
Gottlieb A., Keydor I., Epstein HT: Rodent brain growth stages. An analytical review. Biol Neonate1977;32:166-167.
3.
Mares P., Trojan S.: Ontogenetic development of isonicotinehydrazide-induced seizures in rats. Brain Dev1991;13:121-125.
4.
Velisek L., Kubová H., Pohl M., et al: Pentylenetetrazol-induced seizures in rats: An ontogenetic study . Naunyn Schmiedebergs Arch Pharmacol1992 ;346:588-591.
5.
Zouhar A., Mares P., Liskova-Bernaskova K., et al: Motor and electrocorticographic epileptic activity induced by bicuculline in developing rats. Epilepsia1989;30:501-510.
6.
Swann JW, Brady RJ: Penicillin-induced epileptogenesis in immature rats' CA3 hippocampal pyramidal cells. Dev Brain Res1984;12:243-254.
7.
Michelson HB , Lothman EW: An in vivo electrophysiologic study of the ontogeny of excitatory and inhibitory processes in rat hippocampus . Dev Brain Res1989;46:113-122.
8.
Coyle JT, Enna SJ: Neurochemical aspects of the ontogenesis of GABAergic neurons in the rat brain . Brain Res1976;111:119-133.
9.
Xu SG, Garant DS, Sperber EF, et al: The proconvulsant effect of nigral infusion of THIP on flurothyl-induced seizures in rat pups. Dev Brain Res1992;68:275-277.
10.
Moshé SL, Garant DS: Substantia nigra GABA receptors can mediate anticonvulsant or proconvulsant effects. Epilepsy Res, in press.
11.
Moshé SL: Seizures in the developing brain. Neurology1993; 43: (Suppl 5):S3-S7.
12.
Veliskova J. , Velisek L., Ptachewich Y., et al: Baclofen is anticonvulsant in 15-day old and older rats, but proconvulsant in 9-day-old rat pups. Electroencephalogr Clin Neurophysiol, in press.
13.
Lockman LA, Kriel R., Zaske D., et al: Phenobarbital dosage for control of neonatal seizures. Neurology1979;29:1445-1449.
14.
Painter MJ, Pippenger C., MacDonald H., Pitlick W.: Phenobarbital and diphenylhydantoin levels in neonates with seizures . J Pediatr1978;92:315-319.
15.
Gilman JT, Gal P., Duchowny MS, et al: Rapid sequential phenobarbital treatment of neonatal seizures . Pediatrics1989;83: 674-678.
16.
Gal P., Toback J., Boer HR, et al: Efficacy of phenobarbital monotherapy in treatment of neonatal seizures—relationship to blood levels. Neurology1982;32:1401-1404.
17.
Houghton GW , Richens A., Toseland PA, et al: Brain concentrations of phenytoin, phenobarbitone and primidone in epileptic patients. Eur J Clin Pharmacol1975;9: 73-78.
18.
Onishi S., Yoshihi O., Nishimura Y., et al: Distribution of phenobarbital in serum, brain and other organs from pediatric patients. Dev Pharmacol Ther1984;7:153-159.
19.
Painter MJ, Pippenger CE, Wasterlein C., et al: Phenobarbital and phenytoin in neonatal seizures: Metabolism and tissue distribution. Neurology1981;31:1107-1112.
20.
Sherwin AL, Eisen AA, Sokolowski CD: Anticonvulsant drugs in human epileptogenic brain. Arch Neurol1973;29:73-77.
21.
Morselli PL , Pippenger CE: Drug disposition during development: An overview. Am AssocClin Chem1979:1-8.
22.
Radde IC: Mechanisms of drug absorption and their development, in MacLeod SM, Radde IC (eds): Textbook of Pediatric Clinical Pharmacology. Littleton, MA, PSG Publishing, 1985 , pp 17-43.
23.
Agunod M., Yomaguchi N., Lopez R., et al: Correlative study of hydrochloric acid, pepsin and intrinsic factor secretion in newboms and infants. Am J Dig Dis1969;14:400-414.
24.
Grand RJ, Watkins JB, Torti FM: Development of the human gastrointestinal tract: A review. Gastroenterology1976;70:790-810.
25.
Leff RD, Fischer LJ, Roberts RJ: Phenytoin metabolism in infants following intravenous and oral administration . Dev Pharmacol Ther1986;9:217-223.
26.
Morselli PL: Development of physiological variables important for drug kinetics , in Morselli PL, Pippenger CE, Penry JK (eds): Antiepileptic Drug Therapy in Pediatrics. New York , Raven Press, 1983, pp 1-12.
27.
Nelson JD, Shelton S., Kusmiesz HT, Haltalin KC: Absorption of ampicillin and nalidixic acid by infants and children with acute shigellosis. Clin Pharmacol Ther1972;13:879-886.
28.
Heimann G.: Enteral absorption and bioavailability in relation to age. Eur J Clin Pharmacol1980;18:43-50.
29.
Friis-Hansen B.: Body composition during growth: In vivo measurements and biochemical data correlated to differential anatomical growth. Pediatrics1971;47(Suppl):264-274.
30.
Kearns GL, Reed MD: Clinical pharmacokinetics in infants and children—A reappraisal . Clin Pharmacokinet1989;17(Suppl 1): 29-67.
31.
Radde IC: Drugs and protein binding, in MacLeod SM, Radde IC (eds): Textbook of Pediatric Clinical Pharmacology. Littleton, MA, PSG Publishing, 1985, pp 32-43.
32.
Brinkschulte M., Breyer-Pfaff V.: Increased binding of desmethyl-imipramine in plasma of phenobarbital-treated rats. Biochem Pharmacol1982;31:1749-1754.
33.
Tiula E., Neuvomen PJ: Antiepileptic drugs and alphal-acid glycoprotein. N Engl J Med1982;3:1148.
34.
Riva R., Contin M., Albani F., Baruzzi A.: High alpha1-acid glycoprotein concentrations in serum of epileptic children being treated with carbamazepine. Clin Chem1985;31:151.
35.
Bruguerolle B. , Jadot G., Bussiere H.: Together, phenobarbital and carbamazepine lower alpha1-acid glycoprotein concentration in plasma of epileptic patients . Clin Chem1984;30:590.
36.
Zini R., Riant P., Barre J., Tillement JP: Disease-induced variations in plasma protein levels—Implications for drug dosage regiment, part I. Clin Pharmacokinet1990;19:147-159.
37.
Zini R., Riant P., Barre J., Tillement JP: Disease-induced variations in plasma protein levels—Implications for drug dosage regiment, part II. Clin Pharmacokinet1990;19:218-229.
38.
Litterst CL, Mimnaugh EG, Reagan RL: Comparison of in vitro drug metabolism by lung, liver and kidney of several common laboratory species. Drug Metab Dis1975;3:165-259.
39.
Bach B., Hansen JM, Kampmann JP, et al: Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet1981;6:389-396.
40.
Gilman JT: Intractable childhood epilepsy: Issues in pharmacotherapy. J Epilepsy1990;3(Suppl):21-24.
41.
Suzuki Y., Cox S., Hayes J., Walson PD: Carbamazepine age-dose ratio relationship in children. Ther Drug Monit1991;13:201-208.
42.
Battino D., Bossi L., Croci D., et al: Carbamazepine plasma levels in children and adults: Influence of age, dose and associated therapy. Ther Drug Monit1980;2:315-322.
43.
Hall K., Otten N., Johnston B., et al: A multivariable analysis of factors governing the steady-state pharmacokinetics of valproic acid in 52 young epileptics. J Clin Pharmacol1985;25: 261-268.
44.
Whelan HT, Hendeles L., Haberkern CM, Neims AH: High intravenous phenytoin dosage requirement in a newborn infant . Neurology1983;33:106-108.
45.
Gilman JT, Duchowny M.: Childhood epilepsy: Current therapeutic recommendations. CNSDrugs1994;1:180-192.
46.
Pynnonen S. , Sillanpaa M., Frey H., Iisalo E.: Carbamazepine and its 10,11-epoxide in children and adults with epilepsy. Eur J Clin Pharmacol1977;11:129-133.
47.
Battino D., Avanzini G., Bossi L., et al: Plasma levels of primidone and its metabolite phenobarbital: Effect of age and associated therapy. Ther Drug Monit1983;5:73-79.
48.
Scheffner D. , Konig ST, Rautergerg-Ruland I., et al: Fatal liver failure in 16 children with valproate therapy. Epilepsia1988; 29:530-542.
49.
Shear NH, Spielberg SP: Anticonvulsant hypersensitivity syndrome: In vitro assessment of risk . J Clin Invest1988;82: 1826-1832.
50.
Pippenger CE: Maturation of biotransformation rates, in Morselli PL, Pippenger CE, Penry JK (eds): Antiepileptic Drug Therapy in Pediatrics. New York, Raven Press , 1983, pp 333-338.
51.
Herranz JL, Armuo JA, Arteaga R.: Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children. Epilepsia1988;29:794-804.
52.
Falconer MA , Davidson S.: Coarse features in epilepsy as a consequence on anticonvulsant therapy. Report of cases in two pairs of identical twins . Lancet1973;2:112-114.
Philstrong BL, Carlson JF, Smith QT, et al: Prevention of phenytoin associated gingival enlargement: A 15 month longitudinal study. J Periodontol1980;51:311-317.
55.
Marshall WR, Lattanzi DA, Weaver GS, et al: Laser excision of type III phenytoin-induced gingival hyperplasia. Special CareDent1987;7:207-210.
56.
Farwell JR, Lee YJ, Hirtz DG, et al: Phenobarbital for febrile seizures—effects on intelligence and on seizure recurrence. N Engl J Med1990 ;322:364-369.
57.
Trimble MR, Cull C.: Children of school age: The influence of antiepileptic drugs on behavior and intellect. Epilepsia1988; 29(Suppl 3):S15-S19.
58.
Vining EPG , Mellits ED, Dorsen MM, et al: Psychologic and behavioral effects of antiepileptic drugs in children: A double-blind comparison between phenobarbital and valproic acid . Pediatrics1987;80:165-174.
59.
Gallassi R. , Morreale A., Lorusso S., et al: Carbamazepine and phenytoin. Comparison of cognitive effects in epileptic patients during monotherapy and withdrawal . Arch Neurol1988 ;45: 892-894.
60.
Dreifuss FE , Santilli N., Langer DH, et al: Valproic acid hepatic fatalities: A retrospective review. Neurology1987;37:379-385.
61.
Coulter DL: Carnitine, valproate, and toxicity. J Child Neurol1991;6:7-14.
62.
Pellock JM: Carbamazepine side effects in children and adults. Epilepsia1987;28(Suppl 3):S64-S70.
